title: Treatment of hot flushes in breast and prostate cancer.
abstract: Hot flushes, the most common health problem reported by menopausal-age women, can lead to significant morbidity and affect the social life, ability to work and sleep pattern of the sufferer. Women treated for breast cancer and men receiving androgen ablation for prostate cancer experience hot flushes that are more frequent, severe and longer lasting than those experienced by the general menopausal population. In women with breast cancer, hot flushes can result from chemotherapy-induced menopause, hormonal therapy, or ovarian suppression. In men with prostate cancer, hot flushes occur after surgical or medical castration. Hormone replacement therapy with oestrogen-based compounds has been a mainstay of treatment for hot flushes during the perimenopausal period. However, recent studies have shown that, in healthy menopausal women, hormone replacement therapy is associated with an increased risk of breast cancer, myocardial infarction, thrombo-embolic events and stroke. Thus, identifying nonhormonal agents that can control hot-flush symptoms is essential to the quality of life of a growing population of cancer survivors. The most promising agents act on the CNS and include selective serotonin reuptake inhibitors, as well as venlafaxine and gabapentin.
authors.affiliation: Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
authors.forename: Kerin B
authors.initials: KB
authors.lastname: Adelson
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Hershman
mesh_terms: D000588:Amines / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D031885:Cimicifuga; D000075202:Contraindications; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015671:Electroacupuncture; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D019584:Hot Flashes / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000601:surgery; D009919:Orchiectomy / Q000009:adverse effects; D017374:Paroxetine / Q000627:therapeutic use; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D018931:Antineoplastic Agents, Hormonal; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D000077206:Gabapentin; D017374:Paroxetine; D028321:Plant Preparations; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid